Tirzepatide, a new injectable weight-loss drug, reduced the risk of diabetes in patients with obesity and prediabetes by more than 90% over a three-year period, compared with placebo, according to ...

Eli Lilly's tirzepatide has been shown to significantly cut cardiovascular risks in patients with obesity and a form of heart failure with few treatment options, in another big win for the GLP-1 ...

Tirzepatide, a new injectable weight-loss drug with the trade name Zepbound, reduced the risk of diabetes in patients with obesity and prediabetes by more than 90% over a three-year period ...

More than 1,400 units of products bought online that claim to be weight loss medications have been seized by authorities so ...

Three years of tirzepatide also reduced the risk for progression to type 2 diabetes compared with placebo. HealthDay News — For patients with obesity and prediabetes, three years of tirzepatide yields ...

Eli Lilly's dual GLP-1/GIP agonist tirzepatide has been shown to reduce the risk of worsening disease in people with heart failure and obesity in a phase 3 trial, the first to show a benefit on ...

Tirzepatide, a new injectable weight-loss drug with the trade name Zepbound, reduced the risk of diabetes in patients with obesity and prediabetes by more than 90% over a three-year period ...

Tirzepatide, a new injectable weight-loss drug with the trade name Zepbound, reduced the risk of diabetes in patients with obesity and prediabetes by more than 90% over a three-year period, compared ...

The HPRA has issued a serious warning to the public about the dangers of buying GLP-1 medicines, such as semaglutide.

Kuwait: A case study published in the European Journal of Case Reports in Internal Medicine highlights the importance of healthcare practitioners being aware of tirzepatide's potential hepatotoxicity ...

HPRA warns of risks of illegal, counterfeit versions of drugs such as Ozempic and Wegovy, saying they pose ‘significant risk’ ...